Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Amelogenesis Imperfecta with Nephrocalcinosis: A Rare Association in Siblings.

Reddy P, Aravelli S, Goud S, Malathi L.

Cureus. 2019 Jul 1;11(7):e5060. doi: 10.7759/cureus.5060.

PMID:
31516772
2.

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.

Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A, Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K.

J Clin Oncol. 2019 Aug 14:JCO1901154. doi: 10.1200/JCO.19.01154. [Epub ahead of print]

PMID:
31411950
3.

Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer.

Patil V, Noronha V, Joshi A, Chougule A, Kannan S, Bhattacharjee A, Goud S, More S, Chandrasekharan A, Menon N, Srinivas S, Vallathol DH, Dsouza H, Majumdar S, Das S, Zawar A, Khaddar S, Kumar A, Singh G, Kumar KAP, Ravind R, Trivedi V, Behel V, Mahajan A, Janu A, Purandare N, Prabhash K.

EClinicalMedicine. 2019 Apr 9;9:19-25. doi: 10.1016/j.eclinm.2019.03.011. eCollection 2019 Mar.

4.

Investigation of somatic single nucleotide variations in human endogenous retrovirus elements and their potential association with cancer.

Chang TC, Goud S, Torcivia-Rodriguez J, Hu Y, Pan Q, Kahsay R, Blomberg J, Mazumder R.

PLoS One. 2019 Apr 1;14(4):e0213770. doi: 10.1371/journal.pone.0213770. eCollection 2019.

5.
6.

Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study.

Joshi A, Kate S, Noronha V, Patil V, Trivedi V, Goud S, More S, Bhairva S, Prabhash K.

Ecancermedicalscience. 2018 Oct 9;12:876. doi: 10.3332/ecancer.2018.876. eCollection 2018.

7.

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?

Joshi A, Patil V, Noronha V, Chougule A, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K.

Lung India. 2018 Jan-Feb;35(1):27-30. doi: 10.4103/lungindia.lungindia_201_17.

8.

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?

Joshi A, Noronha V, Patil VM, Chougule A, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K.

Chemother Res Pract. 2017;2017:8196434. doi: 10.1155/2017/8196434. Epub 2017 Oct 23.

9.

Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: Feasibility, limitations, and clinical utility in Indian patients.

Zanwar S, Noronha V, Joshi A, Patil VM, Chougule A, Kumar R, More S, Goud S, Janu A, Mahajan A, Prabhash K.

Indian J Cancer. 2017 Jan-Mar;54(1):280-284. doi: 10.4103/ijc.IJC_215_17.

10.

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed-carboplatin chemotherapy.

Noronha V, Patil V, Joshi A, Chougule A, Bhattacharjee A, Kumar R, More S, Goud S, Karpe A, Ramaswamy A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K.

Ecancermedicalscience. 2017 Oct 24;11:776. doi: 10.3332/ecancer.2017.776. eCollection 2017.

11.

Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents.

Noronha V, Joshi A, Patil VM, Banavali SD, Gupta S, Parikh PM, Marfatia S, Punatar S, More S, Goud S, Nakti D, Prabhash K.

Asia Pac J Clin Oncol. 2018 Apr;14(2):e129-e137. doi: 10.1111/ajco.12762. Epub 2017 Aug 28.

PMID:
28849623
12.

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma.

Patil VM, Noronha V, Joshi A, Choughule AB, Bhattacharjee A, Kumar R, Goud S, More S, Ramaswamy A, Karpe A, Pande N, Chandrasekharan A, Goel A, Talreja V, Mahajan A, Janu A, Purandare N, Prabhash K.

ESMO Open. 2017 Apr 27;2(1):e000168. doi: 10.1136/esmoopen-2017-000168. eCollection 2017.

13.

Extra Nasopharyngeal Angiofibroma Simulating a Mucocele: A New Location for the Rare Entity.

Goud S, Swapna T, Bindu H, Shylaja SR.

J Clin Diagn Res. 2017 Jan;11(1):ZD28-ZD30. doi: 10.7860/JCDR/2017/24376.9206. Epub 2017 Jan 1.

14.

Isolation and structural characterization of novel photolytic degradation impurities of Deflazacort using Q-TOF, 2D-NMR and FTIR.

Raju CK, Pandey AK, Ghosh K, Pola A, Goud SK, Jaywant MA, Navalgund SG, Surendranath KV.

J Pharm Biomed Anal. 2017 Jan 30;133:82-89. doi: 10.1016/j.jpba.2016.11.005. Epub 2016 Nov 8.

PMID:
27843100
15.

Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study.

Noronha V, Goswami C, Patil S, Joshi A, Patil VM, Murthy V, Arya S, Juvekar S, Goud S, Prabhash K.

J Laryngol Otol. 2016 Sep;130(9):833-42. doi: 10.1017/S0022215116008513. Epub 2016 Jul 26.

PMID:
27456399
16.

Possible Association Between the Mallampati Score of the Oropharynx and Measures of Tongue Coating, Oral Hygiene and Periodontal Status.

Goud S, Chandra RV, Reddy AA, Reddy BH, Nagarajan S, Naveen A.

Oral Health Prev Dent. 2016;14(5):423-432. doi: 10.3290/j.ohpd.a36469.

PMID:
27351734
17.

Estimation of salivary β-glucuronidase activity as a marker of periodontal disease: A case control study.

Prabhahar CS, Niazi KT, Prakash R, Yuvaraj A, Goud S, Ravishekar P.

J Int Soc Prev Community Dent. 2014 Dec;4(Suppl 3):S193-8. doi: 10.4103/2231-0762.149039.

18.

Dental trauma and mouthguard awareness and use among contact and noncontact athletes in central India.

Tiwari V, Saxena V, Tiwari U, Singh A, Jain M, Goud S.

J Oral Sci. 2014 Dec;56(4):239-43.

19.

The oral health status of patients with renal disease in central India: a preliminary study.

Tiwari V, Saxena V, Bhambhal A, Tiwari U, Singh A, Goud S.

J Ren Care. 2013 Dec;39(4):208-13. doi: 10.1111/j.1755-6686.2013.12040.x.

PMID:
24245972
20.

Ab initio and density functional theory studies on vibrational spectra of 3-hydroxy-3-(2-methyl-1H-indol-3-yl)indolin-2-one.

Vasantha Kumar V, Goud SL, Laxmikanth Rao J.

Spectrochim Acta A Mol Biomol Spectrosc. 2013 Feb 15;103:304-10. doi: 10.1016/j.saa.2012.10.023. Epub 2012 Nov 7.

PMID:
23261627
21.

Plantar pressures in diabetes with no known neuropathy.

Syed N, Maiya AG, Hanifa N, Goud S.

J Diabetes. 2013 Sep;5(3):302-8. doi: 10.1111/1753-0407.12016. Epub 2013 May 29.

PMID:
23190733
22.

Are we eliminating cures with antibiotic abuse? A study among dentists.

Goud SR, Nagesh L, Fernandes S.

Niger J Clin Pract. 2012 Apr-Jun;15(2):151-5. doi: 10.4103/1119-3077.97291.

23.

The Arabidopsis double-stranded RNA-binding protein HYL1 plays a role in microRNA-mediated gene regulation.

Han MH, Goud S, Song L, Fedoroff N.

Proc Natl Acad Sci U S A. 2004 Jan 27;101(4):1093-8. Epub 2004 Jan 13.

24.

Preliminary study to test the feasibility of using a local lymph node type of approach to characterize respiratory allergens.

Goud SN, Anderson PK, Wiescinski CM, Stebbins KE, Landry TD, Holsapple MP.

Toxicol Mech Methods. 2002;12(3):181-94. doi: 10.1080/15376520208951155.

PMID:
20021172
25.
26.

Inhibition of natural killer cell activity in mice treated with tobacco specific carcinogen NNK.

Goud SN, Kaplan AM.

J Toxicol Environ Health A. 1999 Jan 22;56(2):131-44.

PMID:
9972924
27.

Contribution of T lymphocytes to the development of bleomycin-induced pulmonary fibrosis.

Zhu J, Cohen DA, Goud SN, Kaplan AM.

Ann N Y Acad Sci. 1996 Oct 31;796:194-202. No abstract available.

PMID:
8906226
28.

Immunologic alterations in bleomycin-treated mice: role of pulmonary fibrosis in the modulation of immune responses.

Zhu J, Kaplan AM, Goud SN.

Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1924-30.

PMID:
8665057
30.

Immunostimulatory potential of smokeless tobacco extract in in vitro cultures of murine lymphoid tissues.

Goud SN, Zhang L, Kaplan AM.

Immunopharmacology. 1993 Mar-Apr;25(2):95-105.

PMID:
8500987
31.

Priming of peripheral lymph node B cells with TNP-Ficoll: role of lymphokines in B cell differentiation.

Goud SN, Kaplan AM, Subbarao B.

Cell Immunol. 1992 Oct 15;144(2):407-16.

PMID:
1394451
32.
33.
34.
35.

Antibody responses to thymic independent antigens in the peripheral and mesenteric lymph nodes of mice.

Goud SN, Kaplan AM, Subbarao B.

Reg Immunol. 1990 Jan-Feb;3(1):1-7.

PMID:
2121216
36.
37.

Differential responses of B cells from the spleen and lymph node to TNP-Ficoll.

Goud SN, Muthusamy N, Subbarao B.

J Immunol. 1988 May 1;140(9):2925-30.

PMID:
3129503
38.

Sperm shape abnormalities in mice exposed to californium-252 radiation.

Goud SN, Feola JM, Maruyama Y.

Int J Radiat Biol Relat Stud Phys Chem Med. 1987 Nov;52(5):755-60.

PMID:
3316079
39.

Mutagenicity testing of irradiated onions in mice.

Goud SN, Reddi OS, Reddy PP.

Int J Radiat Biol Relat Stud Phys Chem Med. 1982 Mar;41(3):347-9. No abstract available.

PMID:
6978322
40.

Genetic effects of microwave radiation in mice.

Goud SN, Rani MV, Reddy PP, Reddi OS, Rao MS, Saxena VK.

Mutat Res. 1982 Jan;103(1):39-42. No abstract available.

PMID:
7057781
41.

Micronucleus test in mice fed on irradiated whole diet.

Reddy PP, Reddi OS, Pentiah PR, Rani MV, Devi KR, Goud SN.

Int J Radiat Biol Relat Stud Phys Chem Med. 1981 Feb;39(2):217-9. No abstract available.

PMID:
6971832
42.

Dominant lethal mutations induced by 14C in mice.

Goud SN, Reddi OS, Reddy PP.

Experientia. 1981;37(9):948-9. No abstract available.

PMID:
7297656

Supplemental Content

Support Center